Ramez N. Eskander

Oncology

101 The City Dr S
Orange, CA 92868

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 141 publications

Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks.

Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks.

Journal: Hematology/oncology clinics of North America

Published: September 02, 2026

Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.

Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.

Journal: JCO precision oncology

Published: July 10, 2026

Past present and future of radiosensitization in cervical cancer.

Past present and future of radiosensitization in cervical cancer.

Journal: Frontiers in oncology

Published: April 03, 2026

Hitting the mark-or missing it? The promise and peril of biomarkers in endometrial cancer.

Hitting the mark-or missing it? The promise and peril of biomarkers in endometrial cancer.

Journal: Gynecologic oncology

Published: March 19, 2026

Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I.

Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I.

Journal: Gynecologic oncology

Published: February 09, 2026

Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations, part II.

Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations, part II.

Journal: Gynecologic oncology

Published: February 09, 2026

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.

Journal: Journal for immunotherapy of cancer

Published: January 20, 2026

Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.

Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 08, 2026

Successful use of immune checkpoint Inhibition in a patient with myasthenia gravis and recurrent endometrial cancer- expanding access beyond initial clinical trial eligibility.

Successful use of immune checkpoint Inhibition in a patient with myasthenia gravis and recurrent endometrial cancer- expanding access beyond initial clinical trial eligibility.

Journal: Gynecologic oncology reports

Published: October 26, 2025

Double-Blind Randomized Phase 2 Trial Testing Personal Cancer Vaccines in Patients with Advanced Ovarian Cancer.

Double-Blind Randomized Phase 2 Trial Testing Personal Cancer Vaccines in Patients with Advanced Ovarian Cancer.

Journal: Vaccines

Published: September 30, 2025

Ovarian Tumor FAK Inhibition Releases Omega-3 Fatty Acids Stimulating GATA6 Peritoneal Macrophage CXCL13 Production Enhancing Immunotherapy.

Ovarian Tumor FAK Inhibition Releases Omega-3 Fatty Acids Stimulating GATA6 Peritoneal Macrophage CXCL13 Production Enhancing Immunotherapy.

Journal: bioRxiv : the preprint server for biology

Published: September 26, 2025

FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages.

FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages.

Journal: Cell reports

Published: September 05, 2025

Showing 1-12 of 141

Last Updated: 09/26/2026